The effect of Islamic fasting in Ramadan on osteoporosis

The effect of Islamic fasting in Ramadan on osteoporosis

Osteoporosis is considered as one of the most common diseases that women face after their menopause and is caused by both genetic and environmental factors. Dipeptidyl peptidase 4 (DPP-4) gene is one of the important genetic factors contributing in osteoporosis which has a direct and very important...

Full description

Bibliographic Details
Main Authors:	Seyed Mohammad Amin Kormi, Shima Ardehkhani, Mohammad Amin Kerachian
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2017-06-01
Series:	Journal of Fasting and Health
Subjects:	Osteoporosis fasting Dipeptidyl Peptidase 4 Circadian Rhythm
Online Access:	http://jnfh.mums.ac.ir/article_9029_366dbbfb5332d34069dc4ffc23415fc2.pdf

Similar Items

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
by: Song-Chol Mun, et al.
Published: (2020-01-01)

The role of circadian rhythm in osteoporosis; a review
by: Yihao Tian, et al.
Published: (2022-09-01)

Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2
by: Cynthia Melissa Valerio, et al.
Published: (2017-04-01)

Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees
by: Ji Yeon Lee, et al.
Published: (2017-09-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
by: Sachiko Hattori, et al.
Published: (2021-03-01)

Effects of metformin+sitagliptin versus metformin + glibenclamide combinations on lipid profile, body mass index and kidney function in Iraqi patients with type 2 diabetes mellitus.
by: Hassan Mohammed Abbas Al-Temimi, et al.
Published: (2013-06-01)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
by: Jong Ho Kim, et al.
Published: (2016-04-01)

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
by: Yoshia Miyawaki, et al.
Published: (2018-10-01)

Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al.

To fast or not to fast
by: G. Marinho, et al.
Published: (2021-04-01)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
by: Yumie Takeshita, et al.
Published: (2019-05-01)

Pyrazole Incorporated New Thiosemicarbazones: Design, Synthesis and Investigation of DPP-4 Inhibitory Effects
by: Belgin Sever, et al.
Published: (2020-10-01)

The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells
by: Akari Nagamine, et al.
Published: (2017-01-01)

Circadian rhythms in metabolic organs and the microbiota during acute fasting in mice
by: Lauren Pickel, et al.
Published: (2022-07-01)

Recent Evidence on the Impact of Ramadan Diurnal Intermittent Fasting, Mealtime, and Circadian Rhythm on Cardiometabolic Risk: A Review
by: Ahmed S. BaHammam, et al.
Published: (2020-03-01)

Acute pancreatitis with gliptins: Is it a clinical reality?
by: Muthukrishnan Jayaraman, et al.
Published: (2013-01-01)

Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
by: Jie Huang, et al.
Published: (2022-03-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Choosing a Gliptin
by: Vishal Gupta, et al.
Published: (2011-01-01)

Changes in dietary intake, chronotype and sleep pattern upon Ramadan among healthy adults in Jeddah, Saudi Arabia: A prospective study
by: Ameera Alzhrani, et al.
Published: (2022-09-01)

DIPEPTIDYL PEPTIDASE-4 REGULATION OF SDF-1/CXCR4 AXIS: IMPLICATIONS FOR CARDIOVASCULAR DISEASE
by: Jixin eZhong, et al.
Published: (2015-09-01)

Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario
by: Kiran Shah
Published: (2017-06-01)

The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01)

Functional roles of CD26/DPP4 in bleomycin‐induced pulmonary fibrosis
by: Yu Koyanagi, et al.
Published: (2023-03-01)

A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
by: Sibhghatulla Shaikh, et al.
Published: (2021-06-01)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model
by: Shen-Chih Wang, et al.
Published: (2022-03-01)

SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01)

Dipeptidyl Peptidase 4/Midline‐1 Axis Promotes T Lymphocyte Motility in Atherosclerosis
by: Xiaoquan Rao, et al.
Published: (2023-03-01)

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan
by: Sodai Kubota, et al.
Published: (2023-01-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01)

High Levels of Serum DPP-4 Activity Are Associated with Low Bone Mineral Density in Obese Postmenopausal Women
by: Sang-Wook Kim, et al.
Published: (2016-03-01)

Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy
by: Mohammed Abubaker, et al.
Published: (2017-01-01)

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
by: Ira Gantz, et al.
Published: (2017-09-01)

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
by: Manash P Baruah, et al.
Published: (2016-01-01)

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
by: Vaia Lambadiari, et al.
Published: (2021-02-01)

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
by: Hiroshi Takahashi, et al.
Published: (2019-05-01)

Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study
by: Tomonori Sekizaki, et al.
Published: (2021-11-01)